Showing 4111-4120 of 4164 results for "".
- Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with DMEhttps://modernod.com/news/kodiak-sciences-announces-completion-of-12-week-phase-1a-study-of-ksi-301-in-patients-with-diabetic-macular-edema/2476243/Kodiak Sciences reported 12-week data from its phase 1a single ascending dose clinical study of KSI-301, an investigational anti-VEGF antibody biopolymer conjugate, in nine patients with severe diabetic macular edema. After a single dose, eight of nine patients responded to KSI-301, as ass
- Eyenovia Publishes PG21 Phase 2 Trial Results Examining IOP Lowering Effect and Patient Usabilityhttps://modernod.com/news/eyenovia-publishes-pg21-phase-2-trial-results-examining-iop-lowering-effect-and-patient-usability/2479637/Eyenovia announced that the full results of its phase 2 PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose” in the November issue of the peer-
- Interface Biologics Completes Pre-IND Meeting with FDA on Epidel Technology for Treatment of Posterior Inflammatory Eye Diseaseshttps://modernod.com/news/interface-biologics-completes-pre-ind-meeting-with-fda-on-epidel-technology-for-treatment-of-posterior-inflammatory-eye-diseases/2479645/Interface Biologics has announced a positive pre-investigational new drug meeting with the FDA for its dexamethasone intravitreal implant for the treatment of posterior inflammatory eye diseases. The FDA concurred with IBI’s manufacturing and clinical development plans, based on the precl
- Oculis Appoints New Members of Senior Management Teamhttps://modernod.com/news/oculis-appoints-new-members-of-senior-management-team/2479655/Oculis announced the appointments of Fabio Baschiera, PharmD, MPh, PhD, as Vice President of Clinical Development, and Louie-Anne Gauthier, M.Sc., as Vice President of Strategic Marketing, Business Development and Licensing. “We are delighted to welcome Fabio and Louie-Anne to the Oculis m
- RetiPharma Secures Funding to Develop Treatments of Degenerative Eye Disordershttps://modernod.com/news/retipharma-secures-funding-to-develop-treatments-of-degenerative-eye-disorders/2479680/RetiPharma has announced that it has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII). The funding will be used to prepare its lead drug RP001 for a clinical proof-of-concept study in patients with retinal detachment as well as to in source additional compounds usi
- Prospective Study for NaturalVue Multifocal Demonstrates Decreased Refractive Error Change in Fast-Progressing Myopic Childrenhttps://modernod.com/news/prospective-study-for-naturalvue-multifocal-demonstrates-decreased-refractive-error-change-in-fast-progressing-myopic-children/2479681/Thomas Aller, OD, presented updated findings from a prospective clinical trial of NaturalVue (etafilcon A) 1 Day Multifocal Contact Lenses at a briefing for media and industry leaders at the American Academy of Optometry (AAO) Conference in San Antonio on November 9. The NaturalVue portfolio of p
- Clearside Biomedical’s Combination Therapy in RVO Does Not Meet Primary Endpoint in Phase 3 Trialhttps://modernod.com/news/clearside-biomedicals-combination-therapy-in-rvo-does-not-meet-its-primary-endpoint-in-phase-3-trial/2479701/Clearside Biomedical announced that the primary endpoint was not achieved in its phase 3 clinical trial (SAPPHIRE) investigating the superiority of XIPERE (formerly suprachoroidal CLS-TA) used together with the intravitreal anti-VEGF agent Eylea (aflibercept), compared to intravit
- Horizon Pharma Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at AAOhttps://modernod.com/news/horizon-pharma-announces-presentation-of-results-of-48-week-off-therapy-follow-up-to-the-phase-2-trial-of-teprotumumab-at-aao/2479711/Horizon Pharma announced that more detailed results from the 48 week off-therapy follow-up to the phase 2 clinical trial of teprotumumab for people living with moderate-to-severe active thyroid eye disease (TED) were presented at the AAO annual meeting, Oct. 27–30, 2018, in Chicago. The data was
- Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-positive-topline-results-for-its-seecase-phase-2-trial-of-nov03-for-the-treatment-of-patients-with-dry-eye-disease/2479732/Novaliq announces positive topline results for its SEECASE phase 2 clinical trial of NOV03 for the treatment of dry eye disease (DED) in more than 300 patients. NOV03 (100% perfluorohexyloctane) is a preservative-free ophthalmic solution and the first drug developed to treat evaporative DE
- Alcon Expands Surgical Offerings with Portfolio of Mydriatic, Cycloplegic, Diagnostic, and Anesthetic Productshttps://modernod.com/news/alcon-expands-surgical-offerings-with-portfolio-of-mydriatic-cycloplegic-diagnostic-and-anesthetic-products/2479801/Alcon announced that it is expanding its surgical offerings with the addition of a group of products fundamental to many ophthalmic procedures done in the clinic and operating room. These products, which include mydriatic, cycloplegic, diagnostic, and anesthetic products, were transferred from Al